Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome

a non-insulin-dependent, metabolic syndrome technology, applied in the direction of biocide, plant ingredients, sugar derivatives, etc., can solve the problems of increasing the risk of cardiac arrhytmia, many unwanted adverse effects, and patients' hypertension and dyslipidemia, so as to suppress the total cholesterol level, suppress appetite, and suppress fasting plasma triglycerides

Inactive Publication Date: 2005-02-17
STEVIA LTD
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention also relates to various treatment methods for mammals, including treating non-insulin dependent diabetes mellitus, treating meta

Problems solved by technology

However, it will often be necessary to add pharmacological therapy but until today no single drug that simultaneously attacks hyperglycaemia, hypertension and dyslipidemia are available for patients with metabolic syndrome.
This type of treatment is difficult to adjust and administer to the patient and such treatment may result in many unwanted adverse effects which in themselves may need medical treatment.
However if such an action also affects the myocytes in the heart,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
  • Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
  • Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome

Examples

Experimental program
Comparison scheme
Effect test

example 1

As examples of the effects of a compound including the chemical formulas II, stevioside was tested on normal Wistar rats and on GK rats. 2.0 g glucose / kg body weight and 0.2 g stevioside / kg body weight were dissolved in 0.9% saline and infused intravenously. The plasma glucose and insulin levels were measured over a period of 2 hours.

The results are shown in FIGS. 2a, 2b, 3a and 3b, were the O-O series (n=6 for Wistar and n=14 for GK) illustrate glucose infused alone and the {circle over (2)}-{circle over (2)} series (n=6 for Wistar and n=12 for GK) illustrate the combined glucose and stevioside infusion. Data are given as mean±SEM.

After administration of the glucose load, plasma glucose raised immediately and plasma insulin raised abruptly. When stevioside was added together with the glucose, a diminished glucose response was found in the GK-rat and a significant decrease was observed already after 30 min. In the GK rat, stevioside caused a pronounced increase in the insulin r...

example 2

Islet from 6-10 NMRI mice were isolated and incubated in the presence of 16.7 mmol / l and 10−9-10−3 mol / l stevioside or 10−9-10−3 mol / l steviol.

The results of these tests are illustrated in FIGS. 4a and 4b where each column represents mean±SEM from 24 incubations of single islets. Black bars in FIG. 4a indicate that stevioside is present and hatched bars indicate that stevioside is absent.

Black bars in FIG. 4b indicate that steviol is present and hatched bars indicate that steviol is absent.

The figures show that stevioside and steviol are capable of potentiating glucose-stimulated insulin secretion. Further tests confirmed that a stimulatory effect was found already at a very low concentration (above 0.1 nM).

example 3

During a glucose tolerance test, an intravenous bolus of stevioside of 0.2 g / kg body weight was injected in GK rats (the {circle over (2)}-{circle over (2)} serie (n=6)). GK rats receiving 0.9% saline intravenously served as controls (the O-O serie (n=6)). Glucose 2.0 g / kg body weight was administered as a bolus at timepoint 0 min. The plasma glucagon responses are shown as mean±SEM in FIGS. 5a (control) and 5b (GK). The plasma glucagon was suppressed in the stevioside treated GK rat.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Compositionaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to view more

Abstract

A substance including the chemical structures of bicyclo [3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The unique chemical structures of bicyclo [3.2.1]octan alone or in a kaurene structure provides the substances, such as e.g. steviol, isosteviol and stevioside with the capability of enhancing or potentiating the secretion of insulin in a plasma glucose dependent manner. The substances including these unique chemical structures also have the capability of reducing the glucagon concentration in the blood and/or lowering the blood pressure thereby providing a self-regulatory treatment system for non-insulin dependent diabetes mellitus and/or hypertension. In a combination drug which also comprise a soy protein, and/or soy fiber and/or at least one isoflavone these substances act synergistically and such combination drugs are highly useful both prophylacticly or directly in the treatment of e.g. the metabolic syndrome and obesity and has due to the self-regulatory effect a widespread applicability as a dietary supplementation.

Description

TECHNICAL FIELD The present invention relates to a new medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension, metabolic syndromes and other conditions in mammals. BACKGROUND ART Diabetes is a common disease that has a prevalence of 2-4% in the population. Non-insulin dependent diabetes mellitus comprises about 85% of diabetes most commonly occurring at the age above 40 years. The incidence of non-insulin dependent diabetes mellitus is increasing and is at a global level expected to surpass 200 million subjects at year 2010. Diabetes is associated with increased morbidity and a 2-4-fold increase in mortality primarily due to cardiovascular diseases and strokes. Non-insulin dependent diabetes mellitus develops especially in subjects with insulin resistance and a cluster of cardiovascular risk factors such as obesity, hypertension and dyslipidemia, a syndrome which first recently has been recognized and is named “The metabolic syndrome” (Alberti K. G...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/015A61K38/00A61K31/045A61K31/19A61K31/352A61K31/7034A61K31/704A61K36/00A61K36/28A61K36/48A61K45/06A61P3/00A61P3/04A61P3/06A61P3/10A61P9/12C07C13/64C07C13/68C07C61/35C07H15/24C07H15/256
CPCA61K31/015C07C13/68A61K31/192A61K31/352A61K31/70A61K31/704A61K36/00A61K36/48A61K38/16A61K45/06C07C61/35C07H15/256A61K31/19C07C2103/86A61K38/168A61K2300/00C07C2603/86A61P3/00A61P3/10A61P3/04A61P3/06A61P5/50A61P9/12
Inventor HERMANSEN, KJELDGREGERSEN, SERENJEPPESEN, PER
Owner STEVIA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap